TickerFacts.

Teva Pharmaceutical Industries Ltd (TEVA): Long-Term Debt

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2014-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Long-Term Debt is for the year ended 2017-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$28.83B
As of 2017-12-31
+49.9%
3-year compound annual growth
$32.52B2009-12-31: $4.06B2010-12-31: $4.80B2011-12-31: $11.39B2012-12-31: $14.14B2013-12-31: $11.20B2014-12-31: $8.57B2015-12-31: $8.36B2016-12-31: $32.52B2017-12-31: $28.83B$28.83B
2009-12-31 Long-Term Debt (USD) 2017-12-31
Period endedLong-Term DebtChange YoYSource filing
2017-12-31$28.83B-11.4%2018-02-12, Balance as of period end
2016-12-31$32.52B+289.1%2018-02-12, Balance as of period end
2015-12-31$8.36B-2.4%2017-02-15, Balance as of period end
2014-12-31$8.57Bn/c2016-02-11, Balance as of period end
2013-12-31$11.20B-20.8%2015-02-09, Balance as of period end
2012-12-31$14.14B+24.1%2014-02-10, Balance as of period end
2011-12-31$11.39B+137.4%2013-02-12, Balance as of period end
2010-12-31$4.80B+18.3%2012-02-17, Balance as of period end
2009-12-31$4.06Bn/a2011-02-15, Balance as of period end